New cast for a new era: preclinical cancer drug development revisited
Grit S. Herter-Sprie, Andrew L. Kung, Kwok-Kin Wong
Grit S. Herter-Sprie, Andrew L. Kung, Kwok-Kin Wong
View: Text | PDF
Science in Medicine

New cast for a new era: preclinical cancer drug development revisited

Abstract

Molecularly targeted agents promise to revolutionize therapeutics by reducing morbidity and mortality in patients with cancer. However, despite an urgent need for more effective anticancer compounds, current preclinical drug evaluations largely fail to satisfy the demand. New preclinical strategies, including the improvement of sophisticated mouse models and co-clinical study designs, are being used to augment the predictive value of animal-based translational cancer research. Here, we review the development of successful preclinical antineoplastic agents, their associated limitations, and alternative methods to predict clinical outcomes.

Authors

Grit S. Herter-Sprie, Andrew L. Kung, Kwok-Kin Wong

×

Figure 2

Co-clinical trials in patients with lung cancer and in GEM models of human lung cancer.

Options: View larger image (or click on image) Download as PowerPoint
Co-clinical trials in patients with lung cancer and in GEM models of hum...
Depicted is a schematic of our recent co-clinical trial assessing selumetinib and docetaxel combination therapy in KRAS-driven lung adenocarcinomas. Murine tumor response evaluation revealed that loss of the tumor suppressor LKB1 serves as a predictive biomarker of treatment outcome (8). The colors of the different GEM models correspond to the color of the data in the bar graph.